Palatin Technologies (PTN) Corporate presentation summary

Technology and expertise

• Focus on melanocortin system, specifically MC4R agonists for syndromic and genetic obesity.

• First to gain FDA approval for a melanocortin agent (Vyleesi® for female sexual dysfunction).

• Demonstrated ability to move programs from discovery to FDA approval.

• Strategy leverages deep expertise in melanocortin biology and chemistry.

Leadership and team

• Leadership team with over 20–40 years of experience in drug development, finance, legal, and business development.

• Extensive backgrounds from major pharma companies and successful track records in R&D and commercialization.

Development pipeline and programs

• Developing next-generation MC4R selective agonists as peptides (weekly injection) and oral small molecules (daily dosing) for rare neuroendocrine diseases.

• Target indications: hypothalamic obesity (HO), Prader-Willi syndrome (PWS), and Bardet-Biedl syndrome (BBS).

• IND filings for peptide and oral programs planned for late 2026 and early 2027, with Phase 1 and 2/3 studies to follow.

• MC4R agonism validated as a target for obesity management; high unmet need in target populations.